Skip to content
Home/Companies/Biotech/Page Therapeutics
PT

Page Therapeutics

Biotech·Switzerland·Active·2yr hold

Page Therapeutics is a biotech company, headquartered in Switzerland.

Entry
2024
Hold
2yr
Status
Active
Est. EV
–

Who owns Page Therapeutics?

Page Therapeutics is currently owned by XGen Venture SGR through XGEN Venture Life Sciences Fund (2022 vintage), since 2024.

Hand-verified · updated 2026-07-23

XGen Venture SGR
Investor
XGen Venture SGR
XGEN Venture Life Sciences Fund · 2022 · Life Sciences VC

Key facts

HQSwitzerland
SectorBiotech
StatusActive

More from XGEN Venture Life Sciences Fund

Other portfolio companies in the same fund.

AAVantgarde
Active
BiotechItaly· 2025
EpilepsyGTx
Active
BiotechUnited Kingdom· 2025
Gesynta Pharma
Active
BiotechSweden· 2025
Nanophoria
Active
BiotechItaly· 2025
Genespire
Active
BiotechItaly· 2024
iOnctura
Active
BiotechSwitzerland· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Active
Amadeus Capital PartnersUK
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings